{"task_id": "20cc37f758f0d4bd", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 42/464)", "text": "ction, life threatening\nAcute Coronary Syndrome\n27\n\n--- Page 49 ---\nDIAGNOSTIC AND PROGNOSTIC ISSUES (CONT\u2019D)\narrhythmia, acute pericarditis, aortic dissection,\nPE, severe symptomatic aortic stenosis\n\u0002\nGOAL\nkeep\non\ntreadmill\nuntil\nsubject\nreaches 85 90% of age predicted heart rate\n(220 age)\n\u0002\nISCHEMIA CRITERIA\n\u00051 mm horizontal or down\nsloping ST # over multiple leads, or ST \" !\nmyocardial ischemia (sens 68%, spc 77%) !\nproceed to angiogram\n\u0002\nINCONCLUSIVE\npremature termination due to\nchest pain/poor exercise tolerance ! proceed\nto pharmacological stress test\n\u0002\nDUKE TREADMILL SCORE\n(exercise time in min\nutes)\n5\u0004(maximum ST # in mm)\n4\u0004(tread\nmill angina index [0=none, 1=non limiting,\n2=exercise limiting]). Low risk \u00055 (4 year sur\nvival 98 99%), moderate risk 10 to +4, high\nrisk \u0006 11 (4 year survival 71 79%)\n\u0002\nDIPYRIDAMOLE/ADENOSINE MIBI\ndipyridamole (Per\nsantine) causes vasodilation. In CAD, the coronary\nartery is already maximally dilated to compensate,\nso addition of dipyridamole will not change\nperfusion to diseased vessel(s) further. This results\nin a relative perfusion mismatch compared to\nareas with normal dilatory reaction. Contraindicated\nin asthma/COPD. Antidote is aminophylline or\ncaffeine\n\u0002\nDOBUTAMINE\nECHOCARDIOGRAPHY\nassesses wall\nmotion abnormalities. Compared to MIBI, echo\ncardiogram is more specific and less sensitive.\nContraindicated in severe hypertension and\narrhythmias\nAPPROACH TO DIAGNOSIS OF STABLE CAD\nstart\nwith history, physical, rest ECG, and CXR. If low prob\nability, do not investigate further. If high probability,\nproceed with management. If intermediate probabil\nity ! stress test ! cardiac CT, MIBI or stress echo !\nangiography\nDIFFERENTIAL DIAGNOSIS OF TROPONIN\nELEVATION\n\u0002\nCARDIAC\nmyocardial infarction, myocarditis, con\ngestive heart failure, pericarditis, vasospasm,\ntachycardia\nwith\nhemodynamic\ncompromise,\ncocaine ingestion\n\u0002\nPULMONARY\npulmonary embolism\n\u0002\nHEPATIC\nliver failure\n\u0002\nRENAL\nchronic kidney disease\n\u0002\nNEUROLOGIC\nstroke, intracranial hemorrhage\n\u0002\nSYSTEMIC\nsepsis, prolonged strenuous exercise\nSERUM MARKERS\n\u0002\nTROPONIN I/T\nrises within 4 6 h, peaks at 18 24 h,\nremains elevated 7 10 days (sens 40% at presen\ntation, 40 70% after 6 9 h of symptoms)\nDIAGNOSTIC AND PROGNOSTIC ISSUES (CONT\u2019D)\n\u0002 CK/CKMB\nrises within 4 6 h, peaks at 18 24 h,\nremains elevated 3 4 days (sens 35 50% at pre\nsentation, 90% after 3 h in ER)\n\u0002\nMYOGLOBIN\nrises within 1 2 h, peaks in few hours\nTherefore, should do markers (e.g. troponin) at least\ntwice separated by 6 8 h and serial ECG. Despite all\nappropriate investigations, MI missed rate is 2 5%\nECG CHANGES IN ACUTE MI\nsee APPROACH TO\nECG p. 62\nTIMI SCORE FOR PATIENTS WITH UNSTABLE\nANGINA/NSTEMI\n\u0002\nSCORING (out of 7)\nage \u000565, \u00053 CAD risk factors,\nknown CAD (stenosis >50%), ASA use within 7\ndays, \u00052 angina episodes within 24 h, \" cardiac\nmarker, ST deviation \u00050.5 mm\n\u0002\nRISK GROUPS\nlow = 0 2, intermediate = 3 4,\nhigh = 5 7. Consider GPIIb/IIIa and early angio\ngraphy with revascularization in intermediate or\nhigh risk groups\n\u0002\nRISK OF DEATH, MI OR REVASCULARIZATION IN 14\nDAYS\n0/1=5%, 2=8%, 3=13%, 4=20%, 5=26%,\n6/7=41%\nTIMI SCORE FOR PATIENTS WITH STEMI\n\u0002\nSCORING (out of 14)\nage (3 points= \u000575, 2\npoints=65 74), any of diabetes, hypertension, or\nangina (1 point), systolic BP \u0006100 mmHg (3\npoints), HR >100 (2 points), Killip II IV (2 points),\nweight <67 kg (1 point), anterior ST elevation or\nLBBB (1 point), time to reperfusion >4 h (1 point)\n\u0002\nRISK OF DEATH IN 30 DAYS\n0=0.8%, 1=1.6%,\n2=2.2%, 3=4.4%, 4=7.3%, 5=12.4%, 6=16.1%,\n7=23.4%, 8=26.8%, >8=35.9%\nIN HOSPITAL OUTCOMES\nNSTEMI\nSTEMI\nDeath\n4%\n6%\nReinfarction\n0.9%\n1.1%\nCardiogenic shock\n2.8%\n6.4%\nStroke\n0.7%\n0.8%\nMajor bleeding\n10%\n12%\nACTION registry 2008/2009 data\nACUTE MANAGEMENT\nABC\nO2 to keep sat >95%, IVs, inotropes, consider\nballoon pump if hemodynamic instability\nPAIN CONTROL\nnitroglycerin (nitro drip 25 mg in\n250 mL D5W, start at 5 mg/min IV, then \" by 5 10 mg/\nmin every 3 5 min to 20 mg/min, then \" by 10 mg/\nmin every 3 5 min up to 200 mg/min, or until relief of\npain, stop titration if SBP is <100 mmHg. Nitro patch\n0.4 mg/h daily. Nitro spray 0.4 mg SL q5min \u00043.\n28\nAcute Coronary Syndrome", "text_length": 4165, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 42/464)", "type": "chunk", "chunk_index": 41, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.289228", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.290091", "status": "complete", "chunks_added": 3}